Glimepiride Vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus
Information source: Sanofi-Aventis
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 2 Diabetes Mellitus
Intervention: glimepiride (Drug); metformin (Drug)
Phase: Phase 3
Sponsored by: Sanofi-Aventis
Official(s) and/or principal investigator(s):
Karen Barch, B.S., Study Director, Affiliation: Sanofi-Aventis
To compare the change in glycemic control from baseline to endpoint (last available
posttreatment assessment) as measured by HbA1c in pediatric subjects with type 2 diabetes
receiving either glimepiride or metformin as monotherapy.
Official title: Glimepiride Versus Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus: A Single Blind Comparison Study
Study design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Change in HbA1c from baseline to Week 24 or last evaluable ontreatment value.
Change in HbA1c from baseline to Week 12
Responder rate, defined as proportion of subjects with HbA1c < 7.0% at Week 24 or last evaluable on-therapy observation
Mean change in fasting SMBG from baseline to each visit at weeks 4, 8, 12, 18 and 24 or last evaluable on-treatment value.
Mean change in fasting plasma glucose (FPG) from baseline to each visit at weeks 4, 8, 12, 18 and 24 or last evaluable on-treatment value.
Percent completers, defined as subjects who continued study medication until completion of all requirements of Visit 6 (Week 18)
Mean change in lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides) from baseline to Wk 24 or last evaluable on-treatment value.
Mean change in body mass index (BMI) from baseline to Wk 12 and Wk 24 or last evaluable on-treatment value
Minimum age: 8 Years.
Maximum age: 17 Years.
1. Subjects who had type 2 diabetes treated with diet and exercise only for at least 2
weeks prior to randomization, or who were previously or currently treated with an oral
agent and had not responded to diet, exercise, and oral therapy for at least 3 months
(documented by an HbA1c >7. 5%).
2. Subjects who completed glimepiride pharmacokinetic Study HOE 490/4045 at preselected
sites within 3 weeks prior to the screening period were also permitted to enroll.
3. Subjects were required to be negative for islet cell antigen (ICA) and glutamic acid
decarboxylase (GAD) autoantibodies and to have a C-peptide level at 90 minutes of ≥
1. 5 ng/mL. The HbA1c was required to be >7. 1% at screening and <12. 0% on the day of
Subjects meeting any of the following criteria were not to be included in the study:
1. A history of an acute metabolic complication such as diabetic ketoacidosis within 3
months before screening
2. On insulin therapy, or had received insulin for >6 weeks, 3 months prior to
3. On weight-reduction medication
4. Known hypersensitivity to biguanides, sulfonamides, or insulin
5. Pregnant or lactating females
6. Clinically significant renal (serum creatinine level >1. 0 mg/dL) or hepatic disease
(alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2. 5 times the
upper limits of normal [ULN])
7. GI disorders that may interfere with the absorption of the study drugs
8. Chronic use of medications known to affect glucose levels such as intermittent use of
systemic corticosteroids or large dose of inhaled steroids
9. Clinically significant laboratory abnormality on screening laboratory tests or any
medical condition that in the opinion of the investigator would affect the outcome of
10. History of drug or alcohol abuse
11. Treatment with any investigational product in the last 3 months before study entry
12. History of noncompliance with regard to follow-up medical care
13. Any disease or condition that in the opinion of the investigator and/or sponsor may
interfere with completion of the study
Locations and Contacts
Sanofi-Aventis, Bridgewater, New Jersey 08807, United States
Starting date: October 2002
Ending date: November 2004
Last updated: July 17, 2006